Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Beckman gains advantage in automated PSA (prostate specific antigen) testing

This article was originally published in Clinica

Executive Summary

Beckman Coulter's recent FDA approval of its automated free PSA test will give it a marketing advantage over Abbott Laboratories, leader in the automated total PSA testing market, as it becomes the first company to sell an automated version of both tests. It will also strengthen Beckman's competitive position with regard to its Access immunoassay system, according to analysts at Morgan Stanley Dean Witter.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT075730

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel